Evidence map›Paper›PMID 32655896›Full record

ReviewNPJ vaccines2020

Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

J Erin Staples, Alan D T Barrett, Annelies Wilder-Smith, Joachim Hombach

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05332197 (Yellow Fever Vaccine Booster Trial in Children- a Phase 3 Clinical Trial to Establish Safety and Immunogenicity of Repeated YF Vaccination in Healthy Gambian Children of Different Ages), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05332197 phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

Yellow Fever Vaccine Booster Trial in Children- a Phase 3 Clinical Trial to Establish Safety and Immunogenicity of Repeated YF Vaccination in Healthy Gambian Children of Different Ages

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2022 to 2023Enrolled750ConditionsYellow FeverArms17D Yellow fever vaccine
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 5 countries.

J Erin StaplesArboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO USA.ORCID 0000-0002-1446-4071
Alan D T BarrettDepartment of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX USA.
Annelies Wilder-SmithInstitute of Public Health, University of Heidelberg, Heidelberg, Germany.
Joachim HombachWorld Health Organization, Geneva, Switzerland.
Centers for Disease Control and Prevention · USHeidelberg University · DEThe University of Texas Medical Branch at Galveston · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

Yellow fever (YF) virus is a mosquito-borne flavivirus found in Sub-Saharan Africa and tropical South America. The virus causes YF, a viral hemorrhagic fever, which can be prevented by a live-attenuated vaccine, strain 17D. Despite the vaccine being very successful at decreasing disease risk, YF is considered a re-emerging disease due to the increased numbers of cases in the last 30 years. Until 2014, the vaccine was recommended to be administered with boosters every 10 years, but in 2014 the World Health Organization recommended removal of booster doses for all except special populations. This recommendation has been questioned and there have been reports of waning antibody titers in adults over time and more recently in pediatric populations. Clearly, the potential of waning antibody titers is a very important issue that needs to be carefully evaluated. In this Perspective, we review what is known about the correlate of protection for full-dose YF vaccine, current information on waning antibody titers, and gaps in knowledge. Overall, fundamental questions exist on the durability of protective immunity induced by YF vaccine, but interpretation of studies is complicated by the use of different assays and different cut-offs to measure seroprotective immunity, and differing results among certain endemic versus non-endemic populations. Notwithstanding the above, there are few well-characterized reports of vaccine failures, which one would expect to observe potentially more with the re-emergence of a severe disease. Overall, there is a need to improve YF disease surveillance, increase primary vaccination coverage rates in at-risk populations, and expand our understanding of the mechanism of protection of YF vaccine.

Indexed as

Public healthViral infection

Identifiers

PMID32655896
PMCPMC7338446
OpenAlexW3038223917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.